2025
Imetelstat in myeloid malignancies: current data and future directions
Bidikian A, Bewersdorf J, Kewan T, Podoltsev N, Stahl M, Zeidan A. Imetelstat in myeloid malignancies: current data and future directions. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-12. PMID: 40116730, DOI: 10.1080/14737140.2025.2482721.Peer-Reviewed Original ResearchMyelodysplastic syndromeLR-MDSClinical trialsPotential disease-modifying propertiesLow-risk myelodysplastic syndromesElevated liver enzymesLR-MDS patientsTreat myelodysplastic syndromeSearch of PubMedTransfusion independenceEssential thrombocythemiaInfusion reactionsMyeloid malignanciesDisease-modifying propertiesCombination therapySurvival benefitEffective telomerase inhibitorImetelstatTelomerase reactivationPatient populationLiver enzymesMyelofibrosisCancer cellsMalignancyConference abstracts
2024
Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman‐Torres K, Rampal R. Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival. European Journal Of Haematology 2024, 114: 238-247. PMID: 39400386, PMCID: PMC11707811, DOI: 10.1111/ejh.14321.Peer-Reviewed Original ResearchSpleen volume reductionOverall survivalOS benefitNon-respondersAssociated with improved OSPatients treated with ruxolitinibAssociated with overall survivalAssociated with significant OS benefitImproved overall survivalSignificant OS benefitPERSIST-2Analysis of survivalUnique survival advantagesInhibitor of Janus kinaseJanus kinaseOS curvesRetrospective analysisSurvival advantageMyelofibrosisPacritinibPatientsRuxolitinibPlateletThrombocytopeniaVolume reduction
2020
Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis.
Schiffer M, Kowalski A, Zhao J, Bewersdorf JP, Lewis RS, Zeidan AM. Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis. Drugs Of Today 2020, 56: 755-768. PMID: 33332482, DOI: 10.1358/dot.2020.56.12.3230206.Peer-Reviewed Original ResearchConceptsSecondary myelofibrosisClinical holdSelective Janus kinase 2 inhibitorNovel oral agentsCommon adverse effectsClinical trial dataFurther drug developmentGastrointestinal symptomsLiver transaminasesOral agentsSymptom burdenJanus kinase 2 inhibitorDrug AdministrationMyeloproliferative neoplasmsTrial dataU.S. FoodAdverse effectsKinase 2 inhibitorPhase IIDrug developmentMyelofibrosisSignificant reductionFurther investigationFedratinibSplenomegaly
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply